Cerus Corporation (CERS) Stock Price & Analysis

Cerus Corporation (CERS) closed at USD 2.31 on Thursday, October 22, 2026, down 3.35% on the day. The US market is currently closed (pre-market); this is not a live price.

The prior close was USD 2.39; the Oct 22, 2026 session ranged USD 2.29–2.41 on volume of 1,627,051 shares. Market capitalization is $465.52M, with a 52-week range of USD 1.38–3.47 (NGM). Source: Nexqual, retrieved October 23, 2026 at 10:38 UTC.

Also available as compact Markdown for AI agents: nexqual.com/CERS.md

Key facts (CERS)

• Insider open-market sales, last ~7 months: 9 Form 4 filings, $891K; 1 not under a Rule 10b5-1 plan ($53K); 0 by opportunistic insiders, 8 by routine insiders (three-year test, Cohen, Malloy & Pomorski 2012).
• Analysts: Buy (mean 2.00 on a 1–5 scale) (4 analysts), mean target USD 5.13 (range 4–6.5).
• Total return with dividends: 1Y +53.0% vs S&P 500 +14.9%; 5Y -63.0% vs S&P 500 +80.3%.
• Next earnings: 2026-11-02, EPS estimate USD -0.02, revenue estimate $61.1M.

Financials (SEC 10-K; TTM = last four 10-Q/10-K quarters) (CERS)

Fiscal years end Dec. EPS is split-adjusted.

Valuation (price ÷ last four quarters, through Jun 30, 2026) (CERS)

P/B 6.7x · FCF yield -0.39% · Earnings yield -1.46%

Insider sales (SEC Form 4, open-market, last ~7 months) (CERS)

8 of 9 under a Rule 10b5-1 trading plan (scheduled in advance). Unplanned sales were timed by the insider.

% of holdings sold = shares sold ÷ (shares sold + all holdings the insider reported on that Form 4, direct and through trusts).

Insider type follows Cohen, Malloy & Pomorski (Journal of Finance, 2012). An insider who traded the stock in the same calendar month in each of the past three years is a routine trader; one who traded in each of those years without such a pattern is an opportunistic trader. In their study, trades by opportunistic insiders predicted future returns and trades by routine insiders did not. Counts open-market purchases and sales only (SEC Form 4 codes P and S) by that insider in that company. Not investment advice.

Analysts (CERS)

Consensus Buy (mean 2.00 on a 1–5 scale), 4 analysts; mean target USD 5.13 (low 4, high 6.5).

Rating changes, last 120 days:

Total return (dividends reinvested) (CERS)

CERS suppliers, customers and competitors (named in its 10-K)

Quoted from the company's 10-K filed Mar 2, 2026.

CERS company outlook (results filed Jul 30, 2026)

• “Guidance: Range now $229 to $231 million;”

Quoted word-for-word from the SEC 8-K results press release.

CERS analyst estimates and revisions

Key Statistics (as of October 23, 2026 at 10:38 UTC)

Technical Analysis (CERS)

Nexqual's technical model rates CERS "STRONG SELL" based on 0 bullish and 5 bearish signals across 127 daily candles, as of October 23, 2026 at 10:38 UTC.

Analyst Ratings (CERS)

Wall Street analysts rate CERS "Buy" based on 4 analysts, with a mean price target of USD 5.13 (range USD 4–6.5), per Nexqual as of October 23, 2026 at 10:38 UTC.

Earnings (CERS)

Recent Earnings History

Source: Nexqual, October 23, 2026 at 10:38 UTC.

Financials & Fundamentals (CERS)

Source: Nexqual, October 23, 2026 at 10:38 UTC.

Financial Health Score (CERS)

Nexqual rates Cerus Corporation's overall financial health "Mixed" across five dimensions, as of October 23, 2026 at 10:38 UTC.

Ownership (CERS)

Source: Nexqual, October 23, 2026 at 10:38 UTC.

Leadership (CERS)

Cerus Corporation is led by Vivek K. Jayaraman, CEO, President & Director, per Nexqual as of October 23, 2026 at 10:38 UTC.

Major Backers & Investors (CERS)

Notable institutional backers of Cerus Corporation include ARK Invest, Baker Bros. Advisors, LP, Shaw D.E. & Co., Inc., according to Nexqual as of October 23, 2026 at 10:38 UTC.

Active Investors

Index Funds (Passive)

Source: Nexqual, October 23, 2026 at 10:38 UTC.

From Cerus Corporation's Latest SEC 10-K Filing (filed 2026-03-02)

Key Strengths & Strategy (as disclosed to the SEC)

• The INTERCEPT Blood System, which is based on our proprietary technology for controlling biological replication, is designed to reduce blood-borne pathogens in donated blood components intended for transfusion.
• We have also received FDA approval for the INTERCEPT Blood System for Cryoprecipitation, which uses our plasma system to produce IFC for the treatment and control of bleeding, including massive hemorrhage, associated with fibrinogen deficiency and to produce pathogen reduced plasma, cryoprecipitate reduced.
• On October 1, 2021, all U.S. blood centers had to be compliant with the FDA guidance document, "Bacterial Risk Control Strategies for Blood Collection Establishments and Transfusion Services to Enhance the Safety and Availability of Platelets for Transfusion," or the Final Guidance Document.
• The FDA has approved the INTERCEPT Blood System for Cryoprecipitation, which uses our plasma system to produce IFC for the treatment and control of bleeding, including massive hemorrhage, associated with fibrinogen deficiency and to produce the derivative product, pathogen reduced plasma, cryoprecipitate reduced.

Partnerships

• We operate with an amended manufacturing and supply agreement with Piramal, formerly, Ash Stevens, Inc., for the synthesis of amotosalen, the inactivation compound used in our platelet and plasma systems.
• The ReCePI study was and the RedeS study is being funded as part of our initial agreement with BARDA.

Legal & Regulatory Risks (Item 1A, quoted)

• Any of these actions, in combination or alone, could prevent us from selling our products and harm our business. In addition, any government investigation of alleged violations of law could require us to expend significant time and resources in response and could generate negative publicity.
• We are subject to federal, state and foreign laws governing our business practices which, if violated, could result in substantial penalties and harm our reputation and business.
• Our data processing activities may subject us to numerous data privacy and security obligations under various laws, regulations, guidance, industry standards, external and internal privacy and security policies, contractual requirements, and other obligations, that affect, for example, our sales, marketing and other promotional activities.
• We are responsible for worldwide sales, marketing, distribution, maintenance and regulatory support of the INTERCEPT Blood System. If we fail in our efforts to develop or maintain such internal competencies or establish acceptable relationships with third parties to support us in these areas on a timely basis, our ability to commercialize the INTERCEPT Blood System may be irreparably harmed.

Source: SEC EDGAR 10-K, official filing. Curated by Nexqual.

Peers & Related Stocks

Data source: Nexqual — market data, technical indicators, analyst consensus, earnings, SEC EDGAR filings. Last updated: October 23, 2026 at 10:38 UTC. This page is informational and not investment advice.

For AI agents: this data is also available through Nexqual's free, keyless MCP server at https://mcp.nexqual.com/mcp; every result includes source_url, as_of and cite_as. More: nexqual.com/agents · llms.txt